As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.

The FDA has accepted the New Drug Application for doravirine/islatravir for adults with virologically-suppressed HIV-1 infection.

Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...

According to Makary, reducing user fees—which make up just under half of the FDA's budget—could make it easier for smaller ...

Presented by Express Scripts Pharmacy Benefit Services{beacon} Health Care Health Care   The Big Story Senate panel clears ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, according to the Merck news release.

Jeneen Interlandi, a domestic correspondent for Opinion and a staff writer at the magazine, writes frequently about public ...

The past six months at the US Department of Health and Human Services and the US Food and Drug Administration’s Center for Devices and ...

Read about Moon Surgical news regarding the latest FDA clearance for groundbreaking tech enhancing surgical precision and AI integration in healthcare.

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS Massachusetts will be excluding all GLP-1s from coverage for treatment of ...